MNKD - NASDAQ
MannKind Corporation
$3.36
-2.0%MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
At a Glance
Live SnapshotMannKind Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
MannKind Corporation Income Statement
MNKD • NASDAQ
| MannKind Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
349M | 285.5M | 199M | 99.8M | 75.4M | 65.1M | 63M | 27.9M | 11.7M | 174.8M | 0.0 | 0.0 | 0.0 | 35K | 50K | 93K | 0.0 | 20K | 10K | 100K | |
GROSS PROFIT | ||||||||||||||||||||
(61.2M) | (76.6M) | (62.8M) | (57.5M) | (38.9M) | (24.6M) | (28M) | (20.5M) | (17.2M) | (50.1M) | (140.4M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
287.8M | 208.9M | 136.2M | 42.3M | 36.6M | 40.5M | 35.1M | 7.4M | -5.5M | 124.7M | -140.4M | 0.0 | 0.0 | 35K | 50K | 93K | 0.0 | 20K | 10K | 100K | |
OPERATING INCOME | ||||||||||||||||||||
(249M) | (136.3M) | (127.5M) | (106.4M) | (83.6M) | (88.4M) | (79.7M) | (88.4M) | (88.9M) | (59.6M) | (204.2M) | (179.6M) | (169.4M) | (147M) | (140.6M) | (152.6M) | (209.8M) | (305.8M) | (307.4M) | (233.8M) | |
(144.1M) | (94.3M) | (94.3M) | (91.5M) | (77.4M) | (59M) | (74.7M) | (79.7M) | (75M) | (46.9M) | (108.4M) | (79.4M) | (59.7M) | (45.5M) | (40.6M) | (40.3M) | (53.4M) | (55.3M) | (50.5M) | (42M) | |
(66.3M) | (45.9M) | (31.3M) | (19.7M) | (12.3M) | (6.2M) | (6.9M) | (8.7M) | (14.1M) | (14.9M) | (29.7M) | (100.2M) | (109.7M) | (101.5M) | (100M) | (112.3M) | (156.3M) | (250.4M) | (256.8M) | (191.8M) | |
38.8M | 72.6M | 8.7M | -64.1M | -47M | -47.9M | -44.6M | -76.6M | -108.2M | 67.3M | -344.7M | -179.6M | -169.4M | -147M | -140.5M | -152.5M | -209.8M | -305.8M | -307.4M | -233.7M | |
PRE-TAX INCOME | ||||||||||||||||||||
(13.8M) | (38M) | (25.2M) | (24.8M) | (16.6M) | (9.5M) | (10.9M) | (9.4M) | (13.3M) | (18.5M) | (24.1M) | (20.4M) | (21.5M) | (21.6M) | (21.8M) | (17.4M) | (10.4M) | (2.3M) | (3.4M) | (0.0) | |
-13.8M | -25.4M | -19M | -22.3M | -16.5M | -9.3M | -9.9M | -8.9M | -13M | -18.4M | -24.1M | -20.4M | -21.5M | -21.6M | -21.8M | -17.3M | -10.4M | 2.8M | 14.4M | 0.0 | |
(38.5M) | -3.9M | (1.9M) | -4.8M | -6.1M | (23.1M) | -1.9M | -437K | (13K) | -597K | (1.4M) | (1.7M) | -635K | -1.2M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-37.4M | -42.1M | -19.1M | -23.3M | -33.9M | -9.5M | -7.3M | -10.1M | -9.1M | 58.4M | -23.8M | -18.8M | -22.1M | -22.8M | -20.3M | -18.1M | -10.3M | 2.7M | 14.2M | 3.2M | |
1.4M | 30.5M | -10.4M | -87.4M | -80.9M | -57.5M | -51.9M | -86.7M | -117.3M | 125.7M | -368.4M | -198.4M | -191.5M | -169.8M | -160.8M | -170.6M | -220.1M | -303M | -293.2M | -230.5M | |
NET INCOME | ||||||||||||||||||||
-4.5M | (2.9M) | (1.6M) | (0.0) | (0.0) | -218K | (0.0) | (240K) | (51K) | (0.0) | (0.0) | (0.0) | (0.0) | -408K | (0.0) | (738K) | (0.0) | (2K) | (3K) | (5K) | |
5.9M | 27.6M | -11.9M | -87.4M | -80.9M | -57.2M | -51.9M | -87M | -117.3M | 125.7M | -368.4M | -198.4M | -191.5M | -169.4M | -160.8M | -170.6M | -220.1M | -303M | -293.2M | -230.5M |
SEC Filings
MNKD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | May 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 28, 2026 | May 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 22, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K/A 8-K/A 2025 (Amended) N/A | December 15, 2025 | October 07, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 08, 2025 | 2025 |
Related Guides
Continue your MNKD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.